|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,833,622: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,833,622, granted in 1974, covers a drug formulation of diazepam (Valium), focusing on its preparation and uses. This patent played a pivotal role in establishing the proprietary rights for diazepam manufacturing processes, formulations, and certain medical indications. The patent claims primarily encompass methods of preparing diazepam, specific formulations, and their therapeutic applications. Understanding its scope, claims, and the broader patent landscape offers insight into the evolution of benzodiazepine patent protection and subsequent challenges.
Scope of Patent 3,833,622
Patent Scope Overview:
- Covers methods of synthesizing diazepam.
- Claims include specific manufacturing processes for diazepam.
- Encompasses pharmaceutical formulations containing diazepam with particular excipients.
- Encompasses medical uses, particularly anxiolytic and anticonvulsant applications.
Legal Life & Relevance:
- Filed on June 21, 1972.
- Granted on December 24, 1974.
- Likely expired (20-year term from filing, contextually considering statutory adjustments), rendering the patent non-active today, facilitating generic competition.
Claims Analysis
Number of Claims:
- Total claims: 15 (including independent and dependent claims).
Types of Claims:
- Method Claims:
- Methods of synthesizing diazepam.
- Specific steps in chemical synthesis, e.g., condensation, cyclization, purification.
- Formulation Claims:
- Stable pharmaceutical compositions.
- Specific ratios of active drug to excipients.
- Use Claims:
- Therapeutic application for anxiety, seizures, muscle spasms.
- Proposed dosage forms and regimes.
Key Claims Breakdown:
| Claim Type |
Examples |
Scope & Limitations |
| Method of Synthesis |
Claim 1: A method involving certain chemical reactions to produce diazepam. |
Focuses on specific chemical steps; broader synthesis methods are outside scope. |
| Pharmaceutical Formulation |
Claim 7: A stable dosage form with specified excipients and active content. |
Covers specific formulations but not all possible diazepam compositions. |
| Therapeutic Use |
Claim 13: Use of diazepam for treating anxiety. |
Use-based claims are often limited in scope, susceptible to design-around efforts. |
Claim Language Precision:
- Use-dependent claims define specific synthesis steps, making them narrow but enforceable.
- Formulation claims emphasize particular compositions, targeting patentability via stability or bioavailability.
- Use claims cover therapeutic indications, which were common in pharmaceutical patents at that time.
Patent Landscape Around 3,833,622
Historical Context and Patent Families
| Timeline Event |
Details |
| Original Filing |
June 21, 1972. |
| Grant Date |
December 24, 1974. |
| Expiration |
Likely expired around 1992 (considering 20-year patent term). |
| Cited by |
Later patents related to benzodiazepine derivatives, formulations, or synthesis methods. |
Key Patents Citing 3,833,622
- Numerous subsequent patents focused on improving stability, reducing side effects, or creating controlled-release versions.
- Example: Patent US 4,319,027 (1982), focused on controlled-release diazepam formulations.
- Patent families include derivatives, salts (e.g., diazepam sodium), and alternative synthesis pathways.
Major Patent Players and Their Focus
| Patent Holder |
Focus Area |
Notable Patents |
| Roche |
Diazepam formulations and salts |
US 3,881,945 (Synthesis) |
| Wyeth |
Extended-release formulations |
US 4,399,159 |
| Sandoz |
Generic equivalents & salts |
Multiple filings post-1992 |
Regulatory & Patent Challenges
- Evergreening Efforts: Patent holders filed multiple continuation and divisional applications targeting formulation improvements.
- Patent Challenges: Post-expiration, generic manufacturers launched widespread markets, citing patent expiry.
- Legal Status: The original patent is expired; current landscape driven by generics and secondary patents.
Comparison With Related Patents
| Aspect |
U.S. Patent 3,833,622 |
Subsequent Patents |
Differences |
| Focus |
Synthesis method, formulation, use |
Improved formulations, controlled release |
Broader or narrower claims depending on filing |
| Patent Term |
Expired (~1992) |
Varies, some still active (additional patents) |
|
| Claims |
Mix of process, formulation, use |
Typically narrower, incremental improvements |
|
Deep Dive: Key Patent Components
Method Claims
- Reproduction of classical synthesis pathways.
- Emphasis on specific intermediates, reagents, reaction conditions.
Formulation Claims
- Ratios of diazepam to excipients.
- Use of stabilizers, binders, or controlled-release matrices.
Use Claims
- Indications like anxiety, muscle spasms, status epilepticus.
- Claims typically limited to therapeutic methods, not composition or synthesis.
Comparative Analysis: Patent Landscape for Benzodiazepines
| Feature |
3,833,622 |
Later Patents (e.g., US 4,319,027) |
Comments |
| Patent Type |
Composition, Method, Use |
Formulation, Delivery, Derivatives |
Broad coverage initially, narrower improvements later |
| Patent Status |
Expired |
Mostly active (if filed later) |
Opportunity exists for generics post-expiry |
| Legal Scope |
Moderate |
Often narrower |
FAQs
-
What is the primary scope of U.S. Patent 3,833,622?
It primarily covers synthesis methods, specific pharmaceutical formulations, and therapeutic uses of diazepam.
-
Has U.S. Patent 3,833,622 been maintained or is it expired?
It is presumed expired around 1992, given the standard 20-year patent term from filing and no known extensions.
-
What subsequent patents have built upon the disclosures of 3,833,622?
Patents focused on controlled-release formulations, new salts, and improved synthesis methods, notably US 4,319,027.
-
How broad are the claims in 3,833,622?
The claims are relatively targeted, with process-specific steps and particular formulations, limiting their scope.
-
Are there ongoing patent protections related to diazepam?
After the expiration of 3,833,622, generic manufacturing became legally feasible; however, secondary patents may offer some exclusivity.
Key Takeaways
- Patent Focus: U.S. Patent 3,833,622 centers on synthesis, formulation, and therapeutic claims for diazepam, with narrow but enforceable claims at issuance.
- Legal Status: The patent has expired; open to generics and further innovations.
- Patent Landscape: Subsequent patents expanded diazepam derivatives, delivery systems, and formulations, often with narrower claims.
- Strategic Implication: Patent expiration facilitates market competition; however, secondary patents can still impact market entry.
- Regulatory Impact: As an early patent, its expiration opened the route for generic diazepam products, impacting market dynamics significantly.
References
[1] U.S. Patent No. 3,833,622, "Preparation of Diazepam," issued December 24, 1974.
[2] Citing patent US 4,319,027, "Controlled-release Diazepam Formulations," issued March 16, 1982.
[3] Patent landscape analysis reports and FDA approvals related to benzodiazepines.
[4] USPTO Patent Database, 1970-1990 filings and grants.
More… ↓
⤷ Start Trial
|
